Compare Dyne Therapeutics Inc. Common Stock (DYN) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs McCormick & Company, Incorporated — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while McCormick & Company, Incorporated trades at $45.36 (market cap $12.02B). The key difference: McCormick & Company, Incorporated is far larger — about 4.2× Dyne Therapeutics Inc. Common Stock's market cap, and McCormick & Company, Incorporated pays a 4.3% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and McCormick & Company, Incorporated for 68 Days on average.
| DYN | MKC | |
|---|---|---|
Market Cap | $2.86B | $12.02B |
Volume | 3,341,579 | 3,822,006 |
Sector | Health | Consumer Staples |
52-Week High | $26.78 | $71.65 |
52-Week Low | $14.60 | $44.14 |
Typical Hold Time | 0 Days | 68 Days |
Enterprise Value | $2.18B | $16.71B |
Dividend Yield | — | 4.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
MKC trades at $44.80, down 1.71% on the day, with a bearish technical signal from moving averages. The company reported strong Q3 2026 earnings of $0.86 per share, beating estimates, driven by 17% sales growth and margin expansion. Valuation ratios appear attractive with a P/E of 8.07 and net income margin of 19.39%. Recent news highlights the acquisition of McCormick de Mexico and a reaffirmed 2026 outlook.
The stock offers value with solid profitability and dividend growth, but faces near-term technical headwinds and mixed analyst sentiment. Upside exists toward the $53.50 consensus target, though execution risks and market volatility require monitoring. The current price near support at $44 suggests a potential entry point for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
